Cassava Sciences 株価情報 (NASDAQ: SAVA)

最新ニュース Cassava Sciences (NASDAQ:SAVA) 株価情報

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) reportedly plans to enter the mobile device market with new accelerated processing unit (APU) chips <a href="https://www.benzinga.com/topic/amd">designed for smartphones. </a>
The chips will leverage Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) 3nm process, extending Taiwan Semiconductor&#8217;s order visibility for 3nm production into late 2026, UDN.com <a href="https://udn.com/news/story/7240/8382001#goog_rewarded" target="_blank" rel="noreferrer noopener">reports</a>.
The new APU chips are rumored to target flagship smartphones, potentially being used in models from Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>).
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25075427/newplot-13.png" alt="" class="wp-image-663223" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25075427/newplot-13.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25075427/newplot-13-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41339315/nvidia-and-intel-competition-threaten-amds-growth-analyst-says" target="_blank" rel="noreferrer noopener">Nvidia and Intel Competition Threaten AMD&#8217;s Growth, Analyst Says</a>
AMD previously collaborated with Samsung on the Exynos 2200 processor, which featured a GPU based on AMD&#8217;s RDNA 2 architecture. However, this earlier partnership focused on graphic enhancements rather than central processor development.
AMD&#8217;s current MI300 series processors, known for their application in AI servers, could lay the groundwork for these upcoming mobile APUs. Industry insiders suggest that Samsung integrate these APUs into its premium devices, which rely heavily on Taiwan Semiconductor-manufactured components, such as Qualcomm Inc processors in the Galaxy S series.
According to Taiwan Semiconductor, its 3nm technology, including N3, N3E, and N3P nodes, has drawn significant interest from major clients like AMD, Apple Inc, and MediaTek. The demand for these advanced chips is so high that Taiwan Semiconductor has tripled its production capacity compared to last year. However, it still needs to work on meeting the overwhelming number of orders.
Taiwan Semiconductor&#8217;s ongoing development of its 3nm family will further address emerging needs in AI, mobile devices, and automotive computing.
AMD posted third-quarter revenue of $6.8 billion, surpassing <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41612007/amd-q3-earnings-revenue-beat-eps-in-line-data-center-up-122-significant-growth-opportunities-ahead-" rel="noreferrer noopener">analyst expectations of $6.71 billion</a>. Revenue grew 18%, driven by a 122% increase in Data Center revenue, which reached $3.5 billion. Client segment revenue rose 29% to $1.9 billion. However, Gaming revenue dropped 69% to $462 million, while Embedded revenue decreased 25% to $927 million.
For the fourth quarter, AMD projects revenue of $7.5 billion, plus or minus $300 million, reflecting 22% growth at the midpoint.
Goldman Sachs analyst&nbsp;Toshiya Hari <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431993/amd-to-benefit-from-ai-competitive-arms-race-goldman-sachs" rel="noreferrer noopener">credited AMD&#8217;s growth</a> to increasing capital investment in AI infrastructure, driven by enterprises in an &#8220;AI arms race.&#8221; AMD&#8217;s robust product pipeline, including competitive GPUs and the integration of ZT Systems, positions the company for accelerated growth.
Rebounding demand for server CPUs and market share gains in enterprise-targeted SKUs will likely boost revenue and margins.
Price Actions: AMD stock is up 2.4% at $141.75 at the last check on Monday. TSM is down 2.6%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42158933/amazons-ai-chip-strategy-targets-nvidias-dominance-in-data-centers" target="_blank" rel="noreferrer noopener">Amazon&#8217;s AI Chip Strategy Targets Nvidia&#8217;s Dominance In Data Centers</a></li>
</ul>
Photo: Shutterstock

Tech

Media

SSNLF

AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market

B. Riley Securities analyst Matt Howlett maintains Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) with a Buy and raises the price target from $16 to $17.

B. Riley Securities Maintains Buy on Abacus Life, Raises Price Target to $17

Following a strong second-quarter performance, Nordstrom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will deliver insights into its third-quarter results Tuesday after-hours. In the second quarter, the company outperformed <a href="https://www.benzinga.com/news/earnings/24/08/40588492/nordstrom-stock-rallies-on-strong-q2-earnings-details">earnings expectations with EPS of $0.96</a>, a 35.21% beat over the consensus estimate of $0.71, driven by strategic pricing and operational efficiencies. 
What Happened: Although quarterly sales of $3.894 billion narrowly missed estimates, they represented a 3.23% year-over-year increase, with digital sales up 6.2% and notable growth in Nordstrom Rack's net sales (+8.8%).
The second quarter gross profit margin of 36.6%—a 155 basis point improvement—showcased Nordstrom's focus on full-price sales and leveraging higher volumes. However, the 8.3% increase in ending inventory relative to sales growth warrants attention as the company balances stock management in a dynamic retail landscape.
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge</a>
For the third quarter, analysts will likely focus on Nordstrom's ability to sustain growth across both banners, particularly Nordstrom Rack, which demonstrated robust performance in the second quarter. 
Comparable sales, which increased 1.9% in the prior quarter, could signal continued consumer resilience amid economic pressures. Margins and inventory levels will remain key indicators of operational efficiency.
Nordstrom's FY guidance of $1.75–$2.05 per share suggests confidence in its growth trajectory. With strategic momentum and a focus on profitability, third quarter results will be a critical checkpoint as the company progresses toward its 2024 objectives.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">Cassava Sciences Alzheimer&#8217;s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies</a>
<h2 class="wp-block-heading">Is JWN A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/JWN">Nordstrom</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/JWN">Nordstrom</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JWN has a 52-week high of $24.93 and a 52-week low of $14.65.

What's Going On With Nordstrom (JWN) Stock?

Walmart&#8217;s CFO, John David Rainey, recently said that if President-elect Donald Trump's proposed tariffs take effect, <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will need to raise prices on certain items.
Speaking with CNBC, Rainey explained, "We never want to raise prices. Our model is everyday low prices. But there probably will be cases where prices will go up for consumers."&nbsp;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
These proposed tariffs include a 10-20% tax on all imports and could go as high as 60-100% on products from China. Retailers like Walmart, AutoZone, Lowe's and others are already speaking out about how these potential changes could make everyday goods more expensive for customers.
The majority of goods Walmart sells are not at risk of tariffs, as about two-thirds of the items sold by Walmart are made, grown or assembled in the U.S. However, tariffs may have a major effect on the remaining one-third of imported goods. In recent years, Walmart has been expanding its supply chain by sourcing from other countries to lessen its reliance on China.
Lowe's CEO Marvin Ellison also expressed concern, saying they're talking to suppliers to understand how the tariffs might affect prices.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a>
Other companies are also taking measures to deal with the tariffs. AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) CEO Philip Daniele, for example, has recently stated that if tariffs are imposed, <a href="https://www.benzinga.com/startups/24/11/42027079/we-will-pass-those-tariff-costs-back-to-the-consumer-says-ceo-of-autozone-heres-a-look-at-other-companies-raising-prices">they will pass those costs onto the consumers</a>. Because AutoZone anticipates the impact on their margins, they even plan to hike prices before the tariffs go into effect. Similarly, Steve Madden intends to shift some of its production to Vietnam, Cambodia and Mexico to lessen its dependency on Chinese production, though price increases are still possible.
<a href="https://www.benzinga.com/news/earnings/24/10/41599361/stanley-black-decker-q3-earnings-revenue-misses-cost-savings-drive-margin-gains-narrows-2024-eps-gu">Columbia Sportswear</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) has also raised concerns, with CEO Tim Boyle mentioning that the company may also have to raise prices. The National Retail Federation also <a href="https://www.benzinga.com/news/24/11/41737933/trump-tariff-proposed-may-cost-americans-78b-in-spending-study">predicted price rises for commonplace goods</a> like apparel, shoes and furniture, warning that these tariffs essentially tax the American people. They anticipate that a $100 coat may increase by up to $21, while a $90 pair of sneakers might cost between $106 and $116.
<a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41451898/what-analysts-are-saying-about-dollar-tree-stock">Dollar Tree</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), which imports many of its products from China, may have to rethink its fixed-price-point model of $1.25 per item if tariffs push costs too high. This could jeopardize the retailer&#8217;s value-focused business strategy by forcing it to either absorb the additional expense or pass it on to customers.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

COLM

DLTR

Walmart CFO Says They Don't Want To Raise Prices, But 'Prices Will Go Up For Consumers' Due To Upcoming Tariffs

Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) with a Buy and raises the price target from $36 to $45.

SRRK

Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $45

High-rolling investors have positioned themselves bullish on Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DDOG often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 16 options trades for Datadog. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $28,125, and 15 calls, totaling $1,025,159.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $185.0 for Datadog over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Datadog's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Datadog's substantial trades, within a strike price spectrum from $100.0 to $185.0 over the preceding 30 days.
<h3>Datadog 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551332_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/03/25</td>
<td>$15.55</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$144.00</td>
<td>$137.5K</td>
<td>100</td>
<td align="right">100</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$65.4</td>
<td>$62.95</td>
<td>$64.45</td>
<td>$100.00</td>
<td>$128.9K</td>
<td>141</td>
<td align="right">27</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.65</td>
<td>$26.35</td>
<td>$26.74</td>
<td>$130.00</td>
<td>$120.0K</td>
<td>6.9K</td>
<td align="right">108</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.55</td>
<td>$26.4</td>
<td>$26.75</td>
<td>$130.00</td>
<td>$106.7K</td>
<td>6.9K</td>
<td align="right">148</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.5</td>
<td>$27.35</td>
<td>$27.5</td>
<td>$160.00</td>
<td>$74.2K</td>
<td>677</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Datadog</h3>
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.
In light of the recent options history for Datadog, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Datadog</h3>
<ul>
<li>Currently trading with a volume of 2,695,586, the DDOG's price is up by 0.89%, now at $156.22. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Datadog</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $150.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Datadog, maintaining a target price of $148. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Datadog, maintaining a target price of $155. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Datadog with a target price of $165. 
&#x2A; An analyst from Scotiabank persists with their Sector Outperform rating on Datadog, maintaining a target price of $133. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Datadog with a target price of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Datadog, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

DDOG

Spotlight on Datadog: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ETN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Eaton Corp.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $26,780, and 10, calls, for a total amount of $449,756.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $270.0 to $390.0 for Eaton Corp over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eaton Corp's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eaton Corp's significant trades, within a strike price range of $270.0 to $390.0, over the past month.
<h3>Eaton Corp Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551327_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.0</td>
<td>$14.0</td>
<td>$14.92</td>
<td>$370.00</td>
<td>$80.4K</td>
<td>1.3K</td>
<td align="right">56</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.0</td>
<td>$18.2</td>
<td>$18.3</td>
<td>$360.00</td>
<td>$75.0K</td>
<td>604</td>
<td align="right">43</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$14.9</td>
<td>$14.0</td>
<td>$14.51</td>
<td>$370.00</td>
<td>$60.0K</td>
<td>1.3K</td>
<td align="right">543</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$14.7</td>
<td>$13.9</td>
<td>$14.56</td>
<td>$370.00</td>
<td>$45.8K</td>
<td>1.3K</td>
<td align="right">456</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$112.2</td>
<td>$108.9</td>
<td>$109.94</td>
<td>$270.00</td>
<td>$43.9K</td>
<td>564</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Eaton Corp</h3>
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
<h3>Eaton Corp's Current Market Status</h3>
<ul>
<li>Trading volume stands at 732,546, with ETN's price down by -0.95%, positioned at $373.81.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 66 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eaton Corp</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $385.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Eaton Corp, targeting a price of $385. 
&#x2A; Reflecting concerns, an analyst from Bernstein lowers its rating to Outperform with a new price target of $382. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Eaton Corp with a target price of $320. 
&#x2A; An analyst from UBS downgraded its action to Buy with a price target of $431. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Eaton Corp, maintaining a target price of $410. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eaton Corp with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Eaton Corp's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bullish move on FedEx. Our analysis of options history for FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $386,945, and 6 were calls, valued at $357,615.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $450.0 for FedEx during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for FedEx's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of FedEx's whale trades within a strike price range from $230.0 to $450.0 in the last 30 days. 
<h3>FedEx Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551322_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$1.3</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$290.00</td>
<td>$115.1K</td>
<td>895</td>
<td>1.0K</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$59.0</td>
<td>$58.05</td>
<td>$59.0</td>
<td>$250.00</td>
<td>$88.5K</td>
<td>739</td>
<td>25</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$149.0</td>
<td>$144.0</td>
<td>$146.35</td>
<td>$450.00</td>
<td>$73.1K</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$144.0</td>
<td>$146.0</td>
<td>$450.00</td>
<td>$73.0K</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$47.0</td>
<td>$46.0</td>
<td>$47.0</td>
<td>$270.00</td>
<td>$65.8K</td>
<td>1.3K</td>
<td>15</td>
</tr>
</tbody>
</table>

<h3>About FedEx</h3>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Following our analysis of the options activities associated with FedEx, we pivot to a closer look at the company's own performance.
<h3>Current Position of FedEx</h3>
<ul>
<li>Trading volume stands at 510,527, with FDX's price up by 2.58%, positioned at $307.7.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 24 days.</li>
</ul>
<h3>What Analysts Are Saying About FedEx</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $348.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on FedEx with a target price of $331. 
&#x2A; An analyst from Barclays persists with their Overweight rating on FedEx, maintaining a target price of $365. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for FedEx with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In FDX Options

Truist Securities analyst Terry Tillman maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and raises the price target from $315 to $380.

Truist Securities Maintains Buy on Salesforce, Raises Price Target to $380

WIIM

Founder Group shares are trading higher after the company announced its proposed acquisition of a majority stake in VES 1 Joint Stock Company.

Stephens &amp; Co. analyst Tim Perz maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Equal-Weight and raises the price target from $61 to $75.

BRBR

Stephens & Co. Maintains Equal-Weight on BellRing Brands, Raises Price Target to $75

TNYA

Tenaya Therapeutics shares are trading higher after the company announced it dosed its first patient with TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial at the University of California, San Francisco.

ALAR

Alarum Technologies shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Josh Beck reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Strong Buy and maintains $675 price target.

Raymond James Reiterates Strong Buy on Meta Platforms, Maintains $675 Price Target

Pseudonymous cryptocurrency trader Jelle shared his portfolio strategy in light of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) approaching $100,000 and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">making a new all-time high.</a>
What Happened: The trader <a href="https://x.com/CryptoJelleNL/status/1860969575220740465">took</a> to X to outline his plans for capitalizing on the uptrend of major cryptocurrencies.
Bitcoin:
Gradually reducing BTC holdings by 1% weekly, increasing to 2% weekly after Bitcoin surpasses $100,000. This ensures exposure to gains while mitigating risk as volatility rises.
<ul>
<li>Taking profits with a 10% sell-off at peak levels, followed by 2% weekly reductions.</li>
</ul>
Solana:
Entered SOL at $20, sold 10% at the all-time high break and will continue reducing the position by 2% per week. 
Ethereum:
Plans to start taking 10% profits when ETH reaches new all-time highs and reduce his position 2$ per week subsequently.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin's Rally Is Stalling Below $100,000</a>
Why It Matters: Jelle emphasizes reducing risk as markets grow more volatile, capitalizing on growth opportunities, and prioritizing profitable outcomes for this cycle. 
His approach encourages other traders to adopt disciplined strategies for managing gains and minimizing potential losses.
Key advice includes funneling profits directly into savings or reinvestment to secure financial wins. &#8220;It&#8217;s time to make some money. Let's make this cycle count,&#8221; Jelle concluded.
The global cryptocurrency market surpassed $3 trillion, with Bitcoin dominance at 57.8%, according to CoinMarketCap. The top ten crypto coins over the past 30 days (highest gains) include altcoins, meme coins and blockchain based tokens.
Among the top-performing cryptocurrencies over the past 30 days are: Peanut The Squirrel (CRYPTO: PNUT), Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) and The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>).
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155010/bitcoins-bull-run-betting-on-a-125k-finish-to-2024">Bitcoin&#8217;s Bull Run: Betting On A $125K Finish To 2024</a></li>
</ul>
Image: Shutterstock

$ADA

$BTC

$DOGE

$ETH

$SAND

$SOL

$XLM

Bitcoin Below $100,000 — Veteran Trader Shares Profit-Taking Strategy

CRGO

Freightos shares are trading lower after the company reported Q3 financial results and issued Q4 revenue guidance with its midpoint below estimates.

Rumble shares are trading higher after the company announced that Dr. Disrespect will provide exclusive content to Rumble Premium and lead Rumble Gaming as an advisor.

Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed<a href="https://www.benzinga.com/news/24/09/41007173/cassava-sciences-stock-rises-on-interim-safety-review-of-simufilam-phase-3-trials"> by the market</a>.
Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock&#8217;s crash Sunday night.
What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, <a href="https://www.benzinga.com/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">sending shares significantly lower </a>to start the trading week.
The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety profile.
"Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease," the company said.
Cassava Sciences CEO Rick Barry called the results "disappointing for patients and their families."
Benzinga reached out to Cassava for comment.
Shkreli, a former hedge fund manager, predicted Monday's sharp shared decline.
"If you have $ on robinhood or interactive, short SAVA now," Shkreli <a href="https://x.com/MartinShkreli/status/1860886801617125798">tweeted </a>at 10:22 p.m. ET Sunday night.
The tweet signaled a belief that Cassava Sciences stock was set to fall. Robinhood and Interactive Brokers are among the brokers who offer 24-hour trading on select stocks, which is why they were named by Shkreli.
Shkreli was asked by several people on X if his tweet was financial advice, to which he replied yes. Shkreli also told people that waiting until Monday's opening bell at 9:30 a.m. ET would be too late to short the stock.
Cassava Sciences shares were halted at 7:25 a.m. ET with the company's update coming at 7:30 a.m. ET and shares resuming for trading at 7:55 a.m. ET.
Shares quickly fell Monday morning by over 80% after the company's update.
The post by Shkreli shouldn't come as a huge surprise since a Nov. 21 thread about a 38-page paper on Cassava by the former hedge fund manager is his pinned <a href="https://x.com/MartinShkreli/status/1859681514415607930">tweet</a>.
"I don't &#x2A;think&#x2A; it doesn't work. It is impossible for it to work," the thread says.
Shkreli said Alzheimer's Disease is a very tough market to target to begin with as 98% of the last Phase 3 trials for the disease have failed. Cassava's Phase 3 treating symptomatic patients could doom it, Shkreli predicted in the thread.
"Cassava bulls are looking for a ‘lotto ticket' return, but their chances are worse than the lotto."
Shkreli was extremely confident in his prediction, with a post <a href="https://x.com/MartinShkreli/status/1860878868028269051">listing </a>the things that he would do if the Phase 3 trial met its primary endpoint.
<ol>
<li>Delete my X account</li>
<li>Shave my head on YouTube and delete that account as well</li>
<li>Begin estrogen therapy and legally change my name to Martina</li>
<li>Move to Haiti, bringing my best friend/cat Nibbles</li>
<li>Retire from business completely</li>
</ol>
Shkreli took aim at WallSteetBets, a subreddit on Reddit Monday with a <a href="https://x.com/MartinShkreli/status/1861031460586831913">tweet </a>saying that "garbage like $SAVA" comes from the subreddit.
Read Also: <a href="https://www.benzinga.com/insights/options/24/11/41817544/looking-at-cassava-sciencess-recent-unusual-options-activity">Looking At Cassava Sciences&#8217;s Recent Unusual Options Activity</a>
Why It's Important: Shkreli said Cassava not meeting the primary endpoint would make the stock "an easy short" and shares could trade near their cash value levels of $2 to $3 per share.
The prediction from Shkreli comes after the former hedge fund manager's wild past in the pharmaceutical sector. Known as "pharma bro" to many, Shkreli previously was CEO of Retrophin and Turing Pharmaceuticals. Shkreli <a href="https://www.benzinga.com/government/21/11/23904774/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro">famously raised the price</a> of antiparasitic drug Daraprim from $13.50 to $750 for insurance providers after Turing acquired the drug.
Shkreli was convicted of securities fraud in 2017 and currently has<a href="https://www.benzinga.com/news/24/10/41222384/pharma-bro-martin-shkreli-loses-appeal-supreme-court-imposes-65m-fine-issues-lifetime-ban-from-pharm"> a lifetime ban</a> from the pharmaceutical sector.
Before his recent Cassava Sciences focus, the former hedge funder has been making recent headlines in <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40185861/djt-trumpcoin-allegedly-launched-by-martin-shkreli-with-barron-trumps-help-tanks-98" target="_blank" rel="noopener">the cryptocurrency sector</a>.
Benzinga reached out to Shkreli for comment and did not hear back by the time of publication.
Citron Research, known for their short reports, praised Shkreli's prediction on Cassava Sciences in a <a href="https://x.com/CitronResearch/status/1861043591369429143">tweet</a>.
"$SAVA illustrates the difficulty in shorting stocks. Has been a clear fraud for years but almost became an impossible short because of the ‘new market forces'. Nice to see some good homework by @martinshkreli added with a dose of reality to achieve real price discovery," Citron Research tweeted.
SAVA Price Action: Cassava Sciences stock is down 84.6% to $4.06 on Monday versus a previous 52-week trading range of $8.79 to $42.20, hitting new 52-week lows.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre">SEC Charges Cassava Sciences Over Manipulated Alzheimer&#8217;s Trial Data, Company And Former Execs Agree To Pay Penalty</a></li>
</ul>
Photo: Wikimedia

Health Care

Movers

Trading Ideas

SAVA

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Raymond James analyst Brian MacArthur maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and lowers the price target from $26 to $25.

GOLD

Raymond James Maintains Outperform on Barrick Gold, Lowers Price Target to $25

Cassava Sciences (SAVA) announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. "I am thrilled to expand Cassava's ...

Cassava Sciences appoints Freda Nassif as Chief Commercial Officer

Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 p...

Cassava Sciences put volume heavy and directionally bearish

Cassava Sciences (SAVA) announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each...

Cassava announces Phase 3 ReThink-ALZ data did not meet co-primary endpoints

Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints

Latest data shows the largest indicative borrow rate increases among liquid option names include: Nano Nuclear Energy Inc (NNE) 96.93% +11.23, Wix....

Largest borrow rate increases among liquid names

In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Cassava Sciences (SAVA – Research Report). The company's share...

JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences' (SAVA) Phase 3 trial for simufil...

D. Boral says Anavex Alzheimer's approach superior to Cassava

09:04 EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer's study miss Published first on TheFly – the ultimate source for real-time, ma...

Cassava Sciences sinks 84% to $4.21 after Alzheimer's study miss

Biggest stock movers Monday: BCOV, BHVN, SAVA, ALAR, and more

ASRT

AVXL

BBWI

BCOV

BHVN

EOSE

GALT

LTBR

NVNXF

SGML

Earnings

Press Releases

Cassava Sciences Reports Q2 2024  Financial Results and Operational Updates

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Management

Cassava Sciences Names Rick Barry as Chief Executive Officer

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Legal

General

Cassava Sciences Resolves SEC Investigation

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

Arvinas

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Harrow

Indivior

Innoviva

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Nuvation Bio

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Pliant Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

HC Wainwright & Co.

Rodman & Renshaw

B. Riley Securities

Cassava Sciences  shares are trading lower after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study.

Comments

Cassava Sciences

ニュース

最新ニュース Cassava Sciences (NASDAQ:SAVA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル